Respironics Acquires BiliChek Line from SpectRx

In a transaction designed to allow the company to focus on diabetes and cancer detection, SpectrX, Inc. (Norcross, GA, USA) has sold its BiliChek noninvasive bilirubin analyzer product line and related assets to Respironics, Inc. (Murrysville, PA, USA) for US$4 million. An additional $1 million is to be paid upon completion of product development, and another $6.25 million in royalties and earn-out payments over the next five years.

Respironics was formerly the exclusive US licensee and distributor of the BiliChek line, which is based on biophotonics technology. By analyzing light reflected from a newborn's forehead, the BiliChek noninvasively predicts the level of bilirubin, the cause of infant jaundice. Previously, the most common method of monitoring infant jaundice was to draw blood from an infant's heel and wait for laboratory results.

"The SpectRx BiliChek device is an excellent fit with out Children's Medical Ventures group,” said James W. Liken, president and CEO of Respironics. "We are excited to expand our involvement with this product line from strictly US distribution to worldwide marketing and sales and also to the future development and manufacturing of the devices.”




Related Links:
SpectRx
Respironics